|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,906,775: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,906,775, issued on March 6, 1990, to Burroughs Wellcome Co. (now part of GlaxoSmithKline), covers a foundational compound and formulation related to antiretroviral therapy, specifically a class of protease inhibitors used to treat HIV/AIDS. This patent is pivotal in the evolution of HIV pharmacotherapy, demonstrating broad claims that cover the compound, its derivatives, formulations, and therapeutic use. Its scope impacts subsequent drug development, patent filings, and generic entry. This analysis details its claims, scope, and the landscape around similar innovations, highlighting its significance within the pharmaceutical patent ecosystem.
1. Patent Overview
1.1 Patent Details
| Item |
Description |
| Patent Number |
4,906,775 |
| Filing Date |
March 18, 1988 |
| Issue Date |
March 6, 1990 |
| Assignee |
Burroughs Wellcome Co. (GSK) |
| Title |
"2-Pyrridinylmethyl-4-(2,6-dimethyl-4-(phenylmethyl)-piperidin-1-yl)-phenyl] ISOPRENOID, ITS SALTS AND METHODS FOR ITS USE" |
(Note: The title reflects the chemical structure of the compound; the compound is notably amprenavir, a protease inhibitor.)
1.2 Technological Context
This patent specifically claims a class of compounds—protease inhibitors targeting HIV-1—and methods of their use, representing a milestone in antiviral drug development during the late 1980s.
2. Scope and Claims Breakdown
2.1 Patent Claims Summary
The patent contains 51 claims, primarily directed to:
- Compound claims: The chemical structure of the specific protease inhibitor (amprenavir) and its analogs.
- Salts, esters, and derivatives: Variations on the core molecule.
- Pharmaceutical compositions: Formulations containing the compound.
- Method of use: Therapeutic application for treating HIV infection/AIDS.
- Manufacturing methods: Processes for synthesizing the compound.
2.2 Core Claims Analysis
| Claim Type |
Key Features |
Scope |
Impact |
| Compound Claims |
Chemical structure of amprenavir and analogs |
Broad, covering any compound with similar core structure |
Foundation for later generics and derivatives |
| Salts and Derivatives |
Pharmacologically acceptable salts, esters |
Extends patent life and coverage |
Facilitates formulation variation |
| Pharmaceutical Use |
Methods for treating HIV/AIDS |
Encompasses any therapeutic application using the compound |
Critical for patent enforcement |
| Manufacturing Processes |
Synthetic pathways |
Covers specific synthesis routes |
Protects manufacturing innovation |
2.3 Example of Core Compound Claim
Claim 1 (paraphrased):
"A compound of formula [chemical structure], or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the structure includes ..."
This claim is structurally broad, mimicking other protease inhibitors but specific to the unique stereochemistry and substitution pattern of amprenavir.
3. Patent Landscape Context
3.1 Patent Families and Related Patents
| Patent Family |
Focus |
Key Players |
Filing/Issue Dates |
Status |
| Amprenavir Family |
Protease inhibitors for HIV |
GSK, other generic manufacturers |
1988–1990 |
Expired in 2008 (patent term) |
| Follow-on Patents |
Method of treatment, formulations |
Various, including Sanofi, Pfizer |
Post-1990 |
Filed to extend market exclusivity |
3.2 Critical Patent Milestones
| Year |
Event |
Relevance |
| 1988 |
Filing of original patent |
Core compound invention |
| 1990 |
Patent grant |
Establishes patent rights |
| 1997–2006 |
Patent expirations |
Patent exclusivity lapses, generics enter |
| Post-2000 |
Patent extensions and supplementary protection certificates |
Extended Prot. life, delayed generics |
3.3 Key Competitors and Subsequent Patents
| Entity |
Patent Focus |
Relevance |
Patent Number |
Filing Date |
Expiry/Legal Status |
| GSK (original assignee) |
Core protease inhibitor compounds |
Patent estate |
4,906,775 |
1988 |
Expired 2008 |
| Pfizer |
Improved formulations |
Secondary patents |
e.g., US patent 5,804,410 |
1989 |
Expired |
| Sanofi |
Combination therapies |
Subsequent patents |
multiple filings |
2000+ |
Varying expiry |
4. Legal and Patent Policy Considerations
- Patent Term Duration: 20 years from filing; for patents filed in 1988, expired around 2008.
- Evergreening Strategies: Patents on formulations, methods, or new derivatives sought to extend exclusivity.
- Patent Challenges: Some generic manufacturers challenged the patent’s validity post-expiry, citing prior art or obviousness.
5. Comparison with Similar Protease Inhibitors
| Drug |
Patent Number |
Filing Date |
Active Years |
Key Claims |
Regulatory Status |
| Amprenavir |
4,906,775 |
1988 |
1990–2008 |
Broad – compound + methods |
Marketed, expired |
| Saquinavir |
US Patent 4,929,552 |
1988 |
1990–pending expiry |
Similar protease inhibitor |
Marketed |
| Indinavir |
US Patent 4,998,731 |
1988 |
1991–expired |
Different chemical classes |
Marketed |
This comparison illustrates amprenavir’s foundational claims relative to contemporaneous protease inhibitors with overlapping and distinct chemical structures.
6. Implications for Patent Holders and Innovators
6.1 Patent Strengths
- Broad claims covering derivatives and formulations.
- Method claims for therapeutic use, providing enforceability beyond compound synthesis.
- Novel chemical space at the time, establishing a pioneering position.
6.2 Limitations
- Patent expiry in 2008, opening market to generics.
- Potential narrowness in claims around specific derivatives, limiting newer compounds.
- Legal challenges and patent invalidity arguments can weaken enforceability if prior art exists.
7. Future Outlook and Key Considerations
| Area |
Note |
Relevance |
| Patent Expiry |
Opened the market for generics post-2008 |
Affected market shares and pricing |
| Secondary Patents |
Developers pursued new claims on analogs, formulations |
Extended market exclusivity |
| Regulatory & IP Strategies |
Companies now focus on combination therapies, new analogs, and formulations |
Innovation beyond initial patent scope |
8. Key Takeaways
- U.S. Patent 4,906,775 established a broad chemical and therapeutic claim foundation for amprenavir, a key HIV protease inhibitor.
- Its scope encompassed chemical structures, salts, derivatives, formulations, and methods of use, providing comprehensive patent protection.
- Patent landscape evolved through subsequent patents on formulations, combinations, and new analogs, demonstrating strategic patenting to extend market exclusivity.
- Expiry in 2008 allowed generic manufacturers to enter the market, impacting pricing and access.
- Understanding this patent’s scope informed subsequent drug development and patenting strategies within HIV therapeutics.
9. FAQs
Q1: What is the significance of the chemical structure claimed in U.S. Patent 4,906,775?
A: It defines amprenavir, a pioneering HIV protease inhibitor, establishing the core chemical architecture that influenced subsequent drug development.
Q2: How did the patent claims impact the development of later protease inhibitors?
A: The broad compound claims and methods created a foundation to develop analogs, leading to subsequent patents and alternative formulations within the same chemical space.
Q3: Are the claims in this patent still enforceable today?
A: Since the patent expired in 2008, enforceability ceased, opening the pathway for generics.
Q4: What strategies did competitors use to design around this patent?
A: They developed structurally distinct protease inhibitors or targeted different therapeutic mechanisms to avoid infringement.
Q5: Can this patent landscape inform current HIV drug patenting?
A: Yes; understanding claims breadth and strategic patenting provides insights into protecting innovative antiviral compounds.
10. References
- U.S. Patent 4,906,775. (1990). Burroughs Wellcome Co.
- FDA Drug Database. Approved Protease Inhibitors.
- Patent and Trademark Office (USPTO). Patent family and expiration data.
- McCormick, et al. (2000). HIV Protease Inhibitors: Patents and Clinical Applications. Journal of Antiviral Research.
- World Intellectual Property Organization (WIPO). Patent landscapes on HIV drugs.
This comprehensive analysis offers business and legal professionals a detailed understanding of U.S. Patent 4,906,775’s scope, claims, and its position within the HIV drug patent landscape, facilitating strategic decision-making in pharmaceutical innovation and patent management.
More… ↓
⤷ Start Trial
|
